Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
OLD MOOT - you need to chill out ! Give us all a break.
Equilibrium....well said...:))
Most of us know the score and are here for longterm....short-tern blips dont deter us......current retrace/fall back is just short-term blip.....as you say last time we went form 40p ro £1.30 within about 1/2 weeks ( 250% rise ).
Many trolls ...are trolling because they have hidden agenda's...
Another thing i would like to point out....whilst most eyes are on cv19 test....one should not forget...up coming completion of Alzheimer’s Disease test ( completion projected for august 2021 )....we also could get news on bladder cancer test update soon aswell...
The RNS most of us are looking forward to is...PARTNERSHIP confirmation..could land anytime.....doubetrs can stay/sit on sidelines and buy in after +ve rns.
Last Point....remember...right now sentiment is low....and has been for few weeks now....it wont last...never did previously in here...everytime we bounced off strongly...
Sng did 600% in one day...after sentiment was low at 35p.......gdr did went up from 40p levels to £1.50 in matter of days when sentiment was low down there...
Most are forgetting from 12p ( lows )....we are still sitting at some +600% ( including special divi ) that 40p + 42.75p = 82.75p
Currently m/c in brh is £15m......i know which undervalued cv19 testing share i would like to be in right now ( brh )...those who disagree are welcome to buy where-ever they deem it to be right.
Good Luck All Genuine Holders
Jizz, sorry Jez, what is your aim on this board? You appear to be laughing about the situation. It is neither funny, troubling or exciting at the moment. Shares rise and fall. It is currently a hold moment. Any lower and I'd suggest buying. However we have all seen the potential in this share. Long term holders like myself are still up after an excellent dividend, in fact I am in profit as long as it remains above 15p. It also went from sub 40p to £1.30 in a matter of days not too long ago. That shows what can happen here. It might not happen next week or month but is likely to rise again before the end of the year on news of the test going into production or another one of our development companies in our portfolio producing the goods in their specific field. So whatever your agenda is it is quite tiresome. Maybe go away, take stock of you actions and investments and return when you have some valid information or informative posts to share with us as at the minute you just appear to be merely winding other board members up.
I like the appointment of Sue Hagan. A very positive step forward and a good person to have onboard.
Did I read someone saying this morning that mm's are filling a large order?
Ha
Ha
Ha
Usual ramping rubbish.
Looks more like Trevors flushing his leftovers down the pan today.. ouch
Come on.. you feel big enough to belittle investors here.. defend your £600m bubble waiting to pop.
I am giving you the platform.. tell me.
Hasn’t sold a single LFT yet let alone received a CE Mark. It’s AVA6000 hasn’t even begun phase 1 trials...? Help me.. I’m curious!
Ok, take the cash off, how do you account for the other £600m?
It is Alans55 not Allans5
That alone should show people that your preaching negativity about this share that you seem to know so much about yet it appears you can't even read.
That is it from me. No more interaction. Have a nice day.
Come on BRH, shut these doom merchants up.
Well... you are still spending day after day after day knocking everything to do with this company valued at a piddly £16m which has a superb, fast and accurate future proof pathogen test and also further width such as sepsis and cancer testing in the pipeline (Covid already surpassed MHRA standards)
I really would pay more attention to that other golden share of yours which spends more money than it makes and valued at over half a billion.
There are some people hell bent on trying to frighten people into selling at what could be huge losses if they purchased at 120 or so, most of whom have" no opinion" under their names yet constantly slate the share and the positive people off.
Shows the kind of people they are when they seem happy at the potential misfortune of others. Are they really worth wasting your time on???
Roquet - I will let you talk to the share price as you are so good at it. Always stick to what you know and you don't know much but you can read the numbers and tell us all what they are. Not very useful though is it!
And the sell off has started again! Don't need to say anymore let the sp do the talking today...!
Roquet. You know clearly don't know what you are talking about. You clearly have never worked in an environment that was anywhere near a company board.
Appointing a non exec director with that specific background is a strategic move.
But yet again you have zero contribution to make other than to be negative about BRH.
Praise the rampers abuse the derampers lok at the sp tells its own story
As a non exec director Sue Hagan will provide advice, review proposals, make recommendations etc etc etc. All positive. Paraytec doesn't need a new COO so they haven't got one. This is about steering. Footsie 100 companies have non exec directors too and consider them very important. They have huge influence and when they ask questions they get answered.
Sue Hagan's appointment is good news. No doubt about it. Not blowing the doors off news on the day it dropped but constructive. It demonstrates professionalism from the company and intent.
Rocquet, if you re-read my post, i haven't called anybody a troll. I have simply advised that the poster is a persistent basher of this company, and to make their own informed decisions. Good day.
Omg.. my whole post was from the Astrimmune website. If you bother to read , click, read some more and research you may learn a few things and stop your rude accusations.
On the Astrimmune website where she is COO.
Astrimmune
Industrial Collaborators
Paraytec (York, UK)
Partner in the development of the FFCI system, Paraytec‘s expertise is in UV imaging instrumentation, with technology licensees serving customers in the pharmaceutical and biopharmaceutical markets
https://www.astrimmune.com
FFCI - Fluid-Flow Cell-Imaging
We are developing FFCI for the detection of cancer cells in body fluids, such as for the detection of bladder cancer using urine samples. Our mission is to devise a simple test (either as a stand-alone test or in conjunction with filter isolation using our Cellexia filters) that is cheap enough to be used in population screening of high risk individuals, as well as for monitoring of existing cancers such as bladder cancer, and also applicable to other cancers based on blood screening. Fluid Flow Cell-Imaging (even in conjunction with chromic stains) is non-destructive, providing the option of post-hoc analysis of isolated cells by molecular techniques such as PCR, RTPCR, genomics and RNAseq and single cell technologies.
Sue Hagan, a pharmacist by profession, with a background in laboratory and project management in the pharmaceutical industry, now runs operations as our COO.